D-0059-2023 Class III Terminated

Recalled by Aadi Bioscience — Pacific Palisades, CA

FDA drug recall D-0059-2023 was initiated by Aadi Bioscience on Oct 13, 2022 and is designated Class III. Reason for recall: Failed Stability Specifications The recall status is terminated (terminated Mar 16, 2023). Affected quantity: 2,333 vials.

Recall details

Product Type
Drugs
Report Date
Nov 23, 2022
Initiation Date
Oct 13, 2022
Termination Date
Mar 16, 2023
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
2,333 vials

Product description

Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.

Reason for recall

Failed Stability Specifications

Distribution pattern

Within the U.S Market - PA, AL, KY, TN

Code information

Lot# 6025701, Expiration Date: 31MAR2023, 100mg/vial, 50 ml single use vial, NDC 80803-153-50.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0059-2023
openFDA file date
Nov 19, 2026
Loaded by RegDataLab
Nov 20, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Need the full FDA record for Aadi Bioscience? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.

Get a free API key

How the connector works

Source: openFDA record for D-0059-2023. Report a data issue: hello@regdatalab.com.